Cash, cash equivalents, and marketable securities of $559.2 million as of December 31, 2024, combined with $165.0 million milestone payment, anticipated to provide cash runway through at least end of 2028
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics participates in a conference call with Truist
- Protagonist Therapeutics: Promising Pipeline and Strategic Partnerships Drive Buy Rating
- Promising Potential of Rusfertide in Treating Polycythemia Vera Drives Buy Rating for Protagonist Therapeutics
- Positive Outlook on Protagonist Therapeutics: Potential of Rusfertide in Addressing Polycythemia Vera Needs